Literature DB >> 24481294

2013 FDA drug approvals.

Asher Mullard.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24481294     DOI： 10.1038/nrd4239

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  26 in total

1.  2014 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 3.  The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry.

Authors:  Faisal Alallaf; Fatima Amanullah H Nazar; Majed Alnefaie; Adel Almaymuni; Omran Mohammed Rashidi; Khalid Alhabib; Fahad Alnouri; Mohamed-Nabil Alama; Mohammad Athar; Zuhier Awan
Journal:  Open Cardiovasc Med J       Date:  2017-07-26

4.  Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.

Authors:  Terry A Day; Keisuke Shirai; Paul E O'Brien; Maria Gisele Matheus; Kristina Godwin; Amit J Sood; Anvesh Kompelli; Julie A Vick; Daniel Martin; Lynn Vitale-Cross; Juan Luis Callejas-Varela; Zhiyong Wang; Xingyu Wu; Olivier Harismendy; Alfredo A Molinolo; Scott M Lippman; Carter Van Waes; Eva Szabo; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2018-11-12       Impact factor: 12.531

5.  Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.

Authors:  Hongyan He; Xiyan Nan; Shuang Liu; Liangren Zhang; Zhenjun Yang; Yun Wu; Lihe Zhang
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

6.  Two decades of publishing excellence in pharmaceutical biotechnology.

Authors:  David B Volkin; Susan Hershenson; Rodney J Y Ho; Susumu Uchiyama; Gerhard Winter; John F Carpenter
Journal:  J Pharm Sci       Date:  2014-12-01       Impact factor: 3.534

7.  IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.

Authors:  Austin W Boesch; Adam R Miles; Ying N Chan; Nana Y Osei-Owusu; Margaret E Ackerman
Journal:  MAbs       Date:  2017-01-05       Impact factor: 5.857

8.  Inhibition of cyclin-dependent kinase CDK1 by oxindolimine ligands and corresponding copper and zinc complexes.

Authors:  Rodrigo Bernardi Miguel; Philippe Alexandre Divina Petersen; Fernando A Gonzales-Zubiate; Carla Columbano Oliveira; Naresh Kumar; Rafael Rodrigues do Nascimento; Helena Maria Petrilli; Ana Maria da Costa Ferreira
Journal:  J Biol Inorg Chem       Date:  2015-09-28       Impact factor: 3.358

Review 9.  Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.

Authors:  Rui Xue Zhang; Ho Lun Wong; Hui Yi Xue; June Young Eoh; Xiao Yu Wu
Journal:  J Control Release       Date:  2016-06-08       Impact factor: 9.776

10.  Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease.

Authors:  Vishnu C Damalanka; Yunjeong Kim; Kevin R Alliston; Pathum M Weerawarna; Anushka C Galasiti Kankanamalage; Gerald H Lushington; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas
Journal:  J Med Chem       Date:  2016-02-08       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.